Company will provide NIAID with R&D services and pilot-lot production for evaluation in clinical studies.

The NIAID awarded Science Applications International (SAIC) a contract extension to provide malaria vaccine production and support services. The seven-year cost-plus-fixed-fee deal has an estimated value of $32.7 million.

The extension represents a follow-on effort for work that the company has been performing for NIAID since 2000. The team will deliver R&D services to support process development and pilot-lot production of promising malaria vaccine candidates into products suitable for evaluation in human clinical studies.

SAIC will serve as the project management arm for these activities. It will work to identify optimal production and purification strategies for clinical-grade malaria immunogens, performing pilot lot production, formulation, preclinical testing, and providing nonclinical development support for promising vaccine candidates, according to SAIC officials.

SAIC will also provide regulatory support for INDs applications.

Previous articleAverion Expands Clinical Research Services through $36.01M Acquisition of Hesperion
Next articleMerck Seals $136M Hep B Vaccine Pact with Dynavax